-+ 0.00%
-+ 0.00%
-+ 0.00%

Genprex Signs Exclusive Patent License Agreement With NYU Langone Health Related To Drug Candidate, Reqorsa Gene Therapy

Benzinga·04/28/2025 11:31:51
Listen to the news

dditional Gene Therapy Technology Expands Genprex's Portfolio of Oncology Licenses

AUSTIN, Texas, April 28, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced it has signed an exclusive patent license agreement with NYU Langone Health related to the drug candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid). The therapy is under investigation as a potential treatment for mesothelioma. The subject patent is co-owned by Genprex and NYU Langone Health, and the license provides Genprex with patent exclusivity.